Advertisement

Primary ADT Provides No Survival Benefit in Localized Prostate Cancer — Physician’s First Watch

Medical News |
July 15, 2014

Primary ADT Provides No Survival Benefit in Localized Prostate Cancer

By Kelly Young

Edited by David G. Fairchild, MD, MPH, and Jaye Elizabeth Hefner, MD

Primary androgen-deprivation therapy (ADT) does not confer a survival advantage in patients with localized prostate cancer, according to an observational study in JAMA Internal Medicine.

Researchers evaluated the survival benefit of primary ADT in nearly 67,000 Medicare patients with stage T1-T2 prostate cancer. Geographic areas in the highest tertile of primary ADT use were compared with those in the lowest tertile.

Overall, areas with high use of primary ADT did not have improved 15-year overall or prostate-cancer-specific survival rates, compared with low-use areas.

While noting the study's limitations, editorialists conclude that based on this study and previous randomized trials, "there is no compelling evidence to prescribe ADT alone for men with localized prostate cancer."

Your Comment

(will not be published)

Filtered HTML

  • Allowed HTML tags: <a> <em> <strong> <cite> <blockquote> <code> <ul> <ol> <li> <dl> <dt> <dd>
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Do you have any conflict of interest to disclose?
CAPTCHA
This question is for testing whether you are a human visitor and to prevent automated spam submissions.
Image CAPTCHA
Enter the characters shown in the image.

Vertical Tabs

* Required

Reader comments are intended to encourage lively discussion of clinical topics with your peers in the medical community. We ask that you keep your remarks to a reasonable length, and we reserve the right to withhold publication of remarks that do not meet this standard.

PRIVACY: We will not use your email address, submitted for a comment, for any other purpose nor sell, rent, or share your e-mail address with any third parties. Please see our Privacy Policy.

Advertisement
Advertisement
Advertisement